- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- December 2024
- 125 Pages
Global
From €3484EUR$3,950USD£3,016GBP
- Report
- August 2025
- 144 Pages
Global
From €2645EUR$2,999USD£2,290GBP
- Report
- August 2025
- 188 Pages
Global
From €3969EUR$4,500USD£3,436GBP
- Report
- June 2025
- 150 Pages
Global
From €2380EUR$2,699USD£2,061GBP
- Report
- June 2025
- 200 Pages
Global
From €2460EUR$2,789USD£2,129GBP
- Report
- June 2025
- 400 Pages
Global
From €4365EUR$4,949USD£3,778GBP
- Report
- May 2023
- 190 Pages
Global
From €2161EUR$2,450USD£1,871GBP
- Report
- January 2019
- 144 Pages
Global
From €2425EUR$2,750USD£2,100GBP
- Report
- January 2022
- 150 Pages
Global
From €5247EUR$5,950USD£4,543GBP
- Report
- November 2023
- 250 Pages
Global
From €2161EUR$2,450USD£1,871GBP
- Report
- January 2024
- 250 Pages
Global
From €7011EUR$7,950USD£6,070GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2866EUR$3,250USD£2,481GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2425EUR$2,750USD£2,100GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2425EUR$2,750USD£2,100GBP

Prostacyclin is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary arterial hypertension, deep vein thrombosis, and coronary artery disease. It works by inhibiting platelet aggregation and reducing the risk of blood clots. Prostacyclin is typically administered intravenously or subcutaneously, and is available in both generic and branded forms. It is also used in combination with other drugs to treat certain conditions.
The prostacyclin market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. These companies include Actelion Pharmaceuticals, Bayer AG, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more